Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diagnostics
Notices of Allowance Received for Bladder Cancer and Colon Cancer Test Kits
May 26th, 1997
Matritech, Inc., Newton, Massachusetts, announced that the company received Notices of Allowance from the United States Patent and Trademark Office for two of its patent applications covering nuclear mitotic apparatus protein (NuMA). NuMA is a structural component of the cell nucleus which is released by dying cells and expressed in relatively large amounts by cancerous cells. Matritech presently sells two cancer diagnostic tests in which the NuMA complex is the tumor marker: the urine-based NMP22 Test Kit for bladder cancer approved for sale in the United States by the FDA; and the blood-based NuMA Test Kit for Colon Cancer which is available overseas and is...
Source: Cancer Weekly (1997-05-26)
|
